A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD)

NCT04853407 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

558

Enrollment

INDUSTRY

Sponsor class

Conditions

Major Depressive Disorder (MDD)

Interventions

DRUG: LY03005 extended-release tablet
DRUG: Placebo

Sponsor

Luye Pharma Group Ltd.